CClinicalTrials.gg
CompletedNCT06478849EDUVVCUpdated Jun 11, 2026

Adherence and Understanding of a Therapeutic Education Program for Patients With Central Venous Access (EDUVVC)

An observational study in Therapeutic Education Program and Prevention, sponsored by Assistance Publique - Hôpitaux de Paris. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-11.

Sponsored by Assistance Publique - Hôpitaux de Paris · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
105
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this project is to evaluate, in a prospective cohort of PICC line patients, adherence to the project and understanding of the messages.

The transmission of knowledge and the acquisition of skills by patients with this type of invasive device will enable them to play an active role in their own care, and could help to reduce the frequency of risks.

This project is part of a collaborative approach that includes the creation of a mobile application for therapeutic education and monitoring (application under development). The evaluation of the device will be the subject of a national PHRC with national structures (SPIADI and PRIMO). The aim is to create a city-hospital collaboration to improve risk management.

Read the detailed description

The ever-increasing use of central venous lines, including PICC lines, and the shift in medical practice towards ambulatory care, are making it increasingly complex to prevent the infectious and non-infectious risks associated with their use.

The involvement of numerous healthcare professionals within and outside the hospital, with varying levels of training, exposes patients to numerous complications, the incidence of which, depending on the device, ranges from 6 to 16%, and occur at the time of insertion (hematoma, pneumothorax, necrosis) or during use (infection, thrombosis, extravasation).

The transmission of knowledge and the acquisition of skills by patients wearing this type of invasive device helps to make the patient a player in his or her own care, and could help to reduce the frequency of risks. As part of a therapeutic education program, we aim to validate the communication tools and messages identified by a panel of French experts. These messages, together with the article published by Petit et al, have enabled us to draw up a skills reference framework for patients with a PICC line.

The aim of this project is to evaluate adherence to the project and understanding of the messages on a prospective cohort of patients.

This project is part of a collaborative approach that includes the creation of a mobile application for therapeutic education and monitoring (application under development). The evaluation of the device will be the subject of a national PHRC with national structures (SPIADI and PRIMO). The aim is to create a city-hospital collaboration to improve risk management.

02

Conditions studied

  • Therapeutic Education Program
  • Prevention

Keywords

  • central venous line
03

In context

Lead sponsor

Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Adult patients with recent PICC line insertion, followed at AVICENNE hospital.

Inclusion criteria

  1. Adult patients over 18 years of age
  2. Patients requiring a PICC line
  3. Patients with a means of communication with an Internet connection (computer or cell phone) or an alternative solution (landline telephone)
  4. Patients with a predicted life expectancy of more than 6 weeks

Exclusion criteria

Exclusion Criteria:

  1. Patient opposed to participating in the study
  2. Patient does not understand French
  3. Patient not affiliated to a French social security scheme
  4. Patient under guardianship or curatorship
  5. Patient under court protection
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
105 participants (actual)
Patient registry
No

Interventions

  • OtherQUESTIONNAIRES

    QUESTINNAIRES / WEBINARS

    Also known as: WEBINARS

06

What researchers measure

Primary outcomes

  1. Assess patients' level of understanding of communication tools.

    The level of comprehension will be assessed on the acquisition of the main messages and will be expressed as a percentage of correct answers.

    Time frame: WEEK 6 POST INCLUSION

Secondary outcomes

  1. Estimating patient adherence to communication tools

    Adherence to communication tools will be assessed by the frequency of participation in the various webinars proposed.

    Time frame: WEEK 6 POST INCLUSION

  2. Identify individual factors : a- Demographic b- Related to underlying pathology c- Management-related

    age, gender, ethnic origin, mother language, lifestyle, place of residence...

    Time frame: week 6 post inclusion

07

Study locations

1 site
  • Hopital Avicenne
    Bobigny, 93000, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 11, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06478849
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Responsible party
Sponsor
First posted
Jun 27, 2024
Start date
Sep 6, 2024
Primary completion
Nov 10, 2025
Completion
Nov 10, 2025
Last update
Jun 11, 2026

Study contacts

CAMILLE REINPRECHT
principal investigator · Hopital AVICENNE

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion